A01K 2217/206
Animal model comprising tissue-specific expression system
Official title: Animal model comprising tissue-specific expression system, e.g. tissue specific expression of transgene, of Cre recombinase
A01K2217/206 (Animal model comprising tissue-specific expression system) appears on 290 US grants and 618 published applications in this corpus.
Search patents in A01K- Granted patents
- 290
- Published applications
- 618
- Assignees
- 324
- Inventors
- 1,268
- Latest grant
- 25 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1996 | 1 | 0 |
| 1997 | 0 | 0 |
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 4 | 0 |
| 2001 | 2 | 0 |
| 2002 | 3 | 1 |
| 2003 | 1 | 2 |
| 2004 | 0 | 5 |
| 2005 | 0 | 5 |
| 2006 | 1 | 2 |
| 2007 | 3 | 1 |
| 2008 | 1 | 5 |
| 2009 | 3 | 8 |
| 2010 | 3 | 38 |
| 2011 | 5 | 36 |
| 2012 | 14 | 24 |
| 2013 | 17 | 33 |
| 2014 | 7 | 19 |
| 2015 | 20 | 37 |
| 2016 | 19 | 35 |
| 2017 | 26 | 26 |
| 2018 | 19 | 41 |
| 2019 | 11 | 50 |
| 2020 | 14 | 38 |
| 2021 | 24 | 33 |
| 2022 | 25 | 44 |
| 2023 | 26 | 33 |
| 2024 | 16 | 42 |
| 2025 | 13 | 36 |
| 2026 | 11 | 24 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Neurodegenerative and amyotrophic model animal25 Aug 2026US 12,714,076 B2Tokyo Metropolitan Institute of Medical Science
- Multi-transgenic pig for Xenotransplantation25 Aug 2026US 12,714,077 B2Revivicor, Inc.
- Compositions comprising miR-690 and methods therefor16 Jun 2026US 12,653,783 B2The Regents of the University of California
- Multitransgenic pigs comprising ten genetic modifications for xenotransplantation9 Jun 2026US 12,648,548 B2Revivicor, Inc.
- Cobra 1/NELF-B as a booster for efficacy of CD8+ T cell-based therapy14 Apr 2026US 12,600,755 B2The George Washington University a Congressionally Chartered Not-for-Profit Corporation
- Non-human animal, kit, and method for producing replacement organ24 Sep 2026US 2026/0283124 A1The Jikei University
- Methods of eliciting immuno-tolerance using soluble immune checkpoint proteins27 Aug 2026US 2026/0250716 A1Duke University
- Genetically modified pig production method, established somatic cell, and raw material for producing genetically modified pig20 Aug 2026US 2026/0240127 A1Pormedtec Co., Ltd.
- Functional nucleic acid molecule and method20 Aug 2026US 2026/0241035 A1The University Court of the University of Edinburgh
- A novel marker for cardiomyocytes dedifferentiation13 Aug 2026US 2026/0235604 A1National University of Singapore
Most cited
By later US patents
- Compositions and methods for the treatment and diagnosis of immune disorders111US 6,562,343 B1Millennium Pharmaceuticals, Inc. · 2003
- Compositions and methods for the treatment and diagnosis of immune disorders106US 6,414,117 B1Millennium Pharmaceuticals, Inc. · 2002
- Compositions and methods for the treatment and diagnosis of immune disorders65US 6,204,371 B1Millennium Pharmaceuticals, Inc. · 2001
- Compositions and methods for the treatment and diagnosis of immune disorders57US 6,288,218 B12001
- Compositions and methods for the treatment and diagnosis of immune disorders56US 6,084,083 AMilennium Pharmaceuticals, Inc. · 2000